David A. Siegel Igm Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 90,500 shares of IGMS stock, worth $110,410. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,500Holding current value
$110,410% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding IGMS
# of Institutions
82Shares Held
16.2MCall Options Held
26.8KPut Options Held
800-
Baker Bros. Advisors LP New York, NY4.1MShares$5 Million0.06% of portfolio
-
Siren, L.L.C. New York, NY3.26MShares$3.97 Million0.21% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.6 Million0.36% of portfolio
-
Black Rock Inc. New York, NY883KShares$1.08 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA876KShares$1.07 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $35.3M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...